EXPANDED ACCESS
Expanded Patient Access to BioXcel Therapeutics’ Investigational Medicines

Expanded Patient Access to BioXcel Therapeutics’ Investigational Medicines


Decision Criteria for Considering an Expanded Access Program
How To Request Early Access
A request for early access to a BioXcel Therapeutics investigational medicine must originate directly from a licensed physician on behalf of his or her patient and should be forwarded to BioXcel Therapeutics at expandedaccess701@bioxceltherapeutics.com (Immuno-Oncology). The requesting physician must agree to obtain appropriate regulatory and ethics committee approvals, as applicable, and to comply with all other safety, monitoring, reporting, and patient consent requirements defined by BioXcel Therapeutics. BioXcel Therapeutics anticipates acknowledging receipt of requests for early access orally or in writing within five (5) business days. BioXcel Therapeutics is committed to evaluating all requests for expanded access in a fair and equitable manner.